Chih-Hao Chen, Ashkan Shoamanesh, Pablo Colorado, Feryal Saad, Robin Lemmens, Gian Marco De Marchis, Valeria Caso, Lizhen Xu, Laura Heenan, Jaime Masjuan, Hanne Christensen, Stuart J Connolly, Pooja Khatri, Hardi Mundl, Robert G Hart, Eric E Smith
BACKGROUND: In the phase 2 PACIFIC-STROKE trial (Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Noncardioembolic Stroke), asundexian, an oral factor XIa inhibitor, did not increase the risk of hemorrhagic transformation (HT). In this secondary analysis, we aimed to investigate the frequency, types, and risk factors of HT on brain magnetic resonance imaging (MRI). METHODS: This was a secondary analysis of the PACIFIC-STROKE trial...
May 1, 2024: Stroke; a Journal of Cerebral Circulation